Shanghai Henlius Biotech (HKG:2696) recorded a rise in attributable profit in the first half of 2025 to 390.1 million yuan from 386.3 million yuan in the year-ago period, a Monday Hong Kong bourse filing said.

The pharmaceutical company's earnings per share were 0.72 yuan in the half year, up from 0.71 yuan in the corresponding period of the last year.

Revenue in the six months rose 2.7% to 2.82 billion yuan from 2.75 billion yuan a year prior.